skip to Main Content
large burst
light ray
upper burst

Unlock the
power of proteins®

Apply our revolutionary CodeEvolver® platform technology to deliver high-performing enzymes and customized solutions in a wide array of applications.

Watch the video


Improve production processes with state-of-the-art enzymes.

Learn More



Create novel therapeutic proteins with highly optimized performance.

Learn More


Food & Beverage

Impact product quality and profitability with expert protein engineering.

Learn More


Life Sciences

Accelerate genomics research and development with powerful enzyme solutions.

Learn More


“[Codexis’] process, which won a 2010 Presidential Green Chemistry Award, increased sitagliptin yield, cut back on production steps, and reduced water use and waste. The advance led to a threefold increase in productivity and helped us avoid the cost of building a second factory to meet rising demand for Januvia.”

R.P. "Skip" Volante, Vice President of R&D

“The partnership with Codexis strengthens our footprint in the enzyme field, a fast-developing part of the nutritional therapy innovation frontier that is changing the way we manage our health.”

Greg Behar, CEO
Nestlé Health Science

“We chose the Codexis platform after a thorough evaluation of the enzyme evolution landscape. Codexis has a significant track record of delivering evolved biocatalysts for pharmaceutical and fine chemical applications over an extended period of time.”

Doug Fuerst, Technology Development Lead, Synthetic Biology

“We view Codexis as an extension of our internal research and development programs at Tate & Lyle and are excited about the opportunities which this partnership brings to deliver new and innovative food ingredients to the market.”

Michael Harrison, Senior Vice President of New Product Development
Tate & Lyle

Latest News

29Aug 18

Codexis to Present at Three Investment Conferences in September

REDWOOD CITY, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at three upcoming investment conferences: H.C. Wainwright 20 th Annual Global investment Conference on Wednesday, September 5,…
read more
08Aug 18

Codexis Reports Second Quarter 2018 Financial Results

Total revenues increase 31% to $13.5 million driven by higher R&D revenue Phase 1a clinical trial for CDX-6114 initiated Conference call begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif. , Aug. 08, 2018 (GLOBE NEWSWIRE) — Codexis, Inc.…
read more
Back To Top
Close search